无认知障碍脑淀粉样血管病患者的tau蛋白范围及其认知意义
本研究为横断面研究,纳入50例无认知障碍的脑淀粉样血管病(CAA)患者和50例年龄性别匹配的健康对照,采用PiB-PET评估淀粉样蛋白、FTP-PET评估tau范围。结果显示CAA患者later PET-Braak分期更常见(46% vs 18%,p=0.003),但多变量模型中later PET-Braak分期仅与年龄和PiB摄取独立相关,与CAA诊断无关;在CAA队列中,later PET-Braak分期与淀粉样负荷相关,但与CAA相关影像标志物或认知评分无关。
要点
- 无认知障碍CAA患者later PET-Braak分期比例高于健康对照(46% vs 18%)。
- 多变量模型中tau范围与年龄和淀粉样负荷相关,与CAA诊断无关。
- CAA队列中tau范围与CAA影像标志物及认知评分均无显著关联。
核心结论
- 在无认知障碍的CAA患者中,tau范围主要由年龄和血管淀粉样负荷驱动,与CAA诊断无独立关联。
- tau范围与CAA相关影像标志物或认知评分无关,提示tau不参与CAA特异性疾病机制。
研究设计与样本
- 横断面研究,纳入50例无认知障碍或痴呆的CAA患者及50例年龄性别匹配的健康对照。
- 所有参与者接受脑MRI、PiB-PET淀粉样蛋白成像和18F-flortaucipir PET tau成像。
- tau范围基于PET-Braak分期分为早期(Braak 0、I-II)与后期(Braak III-VI)。
主要发现
- CAA患者later PET-Braak分期比例为46%,健康对照为18%(p=0.003)。
- 多变量模型中later PET-Braak分期与年龄独立相关(OR 1.19,95%CI 1.07-1.35,p<0.001)及PiB摄取(OR 1.72,95%CI 1.32-2.26,p<0.001),与CAA诊断无关(p=0.264)。
- CAA队列中later PET-Braak分期与更高淀粉样负荷独立相关(OR 1.78,95%CI 1.16-2.73,p=0.008)。
- CAA队列中later PET-Braak分期与CAA相关影像标志物及认知评分均无显著关系(所有p>0.2)。
临床怎么用
- 对于无认知障碍的CAA患者,tau PET异常更可能反映年龄相关或阿尔茨海默病型淀粉样病理,而非CAA本身。
- CAA相关影像标志物和认知评分不能提示tau范围,临床评估tau病理需结合年龄和淀粉样负荷。
局限性
- 横断面设计无法推断因果。
- 样本量有限(CAA和健康对照各50例)。
- 仅纳入无认知障碍的CAA患者,结论不能推广至伴认知障碍的CAA人群。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Despite a well-established amyloid-tau neurodegeneration cascade in Alzheimer disease (AD), the extent and mechanistic relevance of tau pathology in cerebral amyloid angiopathy (CAA), a disease of vascular amyloid deposition, remain unclear. Focusing on patients with CAA without cognitive impairment to minimize concurrent AD pathology, we hypothesized that tau extent would be greater in patients with CAA than in healthy controls (HCs), largely attributable to amyloid burden, but it would not be associated with CAA-related imaging markers or cognitive scores in CAA. METHODS: This cross-sectional study included patients with CAA and age-matched and sex-matched HCs, none of whom had cognitive impairment or dementia. All participants underwent brain MRI, Pittsburgh compound B (PiB)-PET for amyloid, and 18F-flortaucipir (FTP)-PET for tau. Tau extent was estimated based on PET-Braak staging from cortical FTP uptake and categorized into earlier (Braak 0, I-II) vs later (Braak III-VI) PET-Braak stages. Cognitive scores obtained in CAA were standardized z-scores for memory, processing speed, and executive function. Multivariable regression models tested the association of tau extent with (1) CAA diagnosis and amyloid load in the whole cohort [CAA and HC] and (2) amyloid load, CAA-related imaging markers, and cognitive scores within the CAA cohort. RESULTS: The mean age of patients with CAA (n = 50) was 70.3 ± 7.6 years and of HCs was 69.7 ± 7.5 years (p = 0.715) (n = 50); both groups were 56% male. Later PET-Braak stage was more frequent in patients with CAA than in HCs (46% vs 18%, p = 0.003). However, in multivariable models, later PET-Braak stage was independently associated with age (odds ratio [OR] 1.19, 95% CI 1.07-1.35, p < 0.001) and PiB uptake (OR 1.72, 95% CI 1.32-2.26, p < 0.001), but not with CAA diagnosis (p = 0.264). Within the CAA cohort, later PET-Braak stage was again independently associated with higher amyloid burden (OR 1.78, 95% CI 1.16-2.73, p = 0.008) but showed no relationship with CAA-related imaging markers or cognitive scores (all p > 0.2). DISCUSSION: Our results suggest that tau extent is mainly driven by age and vascular amyloid among patients with CAA and that tau extent is not related to CAA-related imaging markers or cognitive scores. These findings further support the view that tau does not affect CAA-specific disease mechanisms among patients with CAA without cognitive impairment.
引用
- Gokcal E, Becker JA, Horn MJ, et al. Extent of Tau and Its Cognitive Implications in Patients With Cerebral Amyloid Angiopathy Without Cognitive Impairment. Neurology. 2026. PMID: 41945879. doi:10.1212/WNL.0000000000214859
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。